Genentech sought regulatory approval for the clinical indication of macular degeneration treatment only for ranibizumab, not for bevacizumab.
Notes on verification
Corroborated by US health policy literature, ophthalmology industry interviews, and EU/Italian/French antitrust regulatory records, all describing the same regulatory strategy independently across different jurisdictions and time periods.
Sources
- Procedura di infrazione da parte dell'Autorità Antitrust (epicentro.iss.it)
- https://www.raps.org/resource/french-regulator-and-roche-trade-blows-over-off-la.html (raps.org)
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4137040/ (pmc.ncbi.nlm.nih.gov)
- https://www.centerforbiosimilars.com/view/an-interview-with-the-american-academy-of-ophthalmology-about-its-bevacizumab-concerns (centerforbiosimilars.com)
- https://www.vbb.com/insights/corporate-commercial-regulatory/french-competition-authority-genentech-novartis-and-roche-fined-eur-444-million-in-saga-involving-wet-age-related-macular-degeneration (vbb.com)
- https://lawhealthtech.com/tag/antitrust/ (lawhealthtech.com)